# Nasal Spray Shows Promise Against Cognitive Decline | Drug Discovery And Development > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/nasal-spray-shows-promise-against-cognitive-decline-drug-discovery-and-development/ > **Published:** 2026-05-27T15:54:34-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T21:52:06-04:00 > **Clinical Summary:** Intranasal CBD and CBG show mechanistic promise for cognitive decline, but human efficacy data remain absent. What clinicians should know. --- ✦ New CED Clinical Relevance #73 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchCBDAgingMental HealthSafetyHemp Why This Matters Clinicians treating [cognitive decline](https://cedclinic.com/cannabis-cognitive-safety-in-older-adults/) may soon have a novel therapeutic option, as [non-intoxicating cannabinoids](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/) delivered via nasal spray demonstrate potential to address neuroinflammation underlying age-related [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/). This development is particularly relevant for patients who cannot tolerate or respond to current [cognitive decline](https://cedclinic.com/cannabis-cognitive-safety-in-older-adults/) therapies, offering a mechanism-based approach targeting specific pathophysiology rather than symptomatic management alone. If these findings advance through [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) successfully, clinicians will need to understand dosing, safety profiles, and integration of cannabinoid-based treatments into standard cognitive disorder management protocols. Clinical Summary A nasal spray formulation combining the [non-intoxicating cannabinoids](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/) cannabidiol (CBD) and cannabigerol (CBG) has demonstrated preliminary promise in preclinical models for mitigating [cognitive decline](https://cedclinic.com/cannabis-cognitive-safety-in-older-adults/) through modulation of neuroinflammation and extracellular pathways associated with aging. This delivery method may offer advantages over oral formulations by achieving direct central nervous system penetration and potentially improving bioavailability of these compounds. The non-intoxicating profile makes this approach potentially suitable for cognitively vulnerable populations, including older adults, who may be reluctant to use THC-containing products. While these findings remain in early development stages and require validation through [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), they suggest a mechanistic basis for investigating cannabinoid-based interventions in neurodegenerative conditions and age-related [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/). Clinicians should monitor emerging clinical trial data on this nasal spray formulation, as a well-tolerated, non-intoxicating option could become a meaningful addition to the limited pharmacologic options currently available for cognitive decline. Dr. Caplan’s Take “What we’re seeing with CBD and CBG in nasal delivery systems is genuinely encouraging for neuroinflammation, but we need to be clear with patients that promise in the lab doesn’t yet equal clinical benefit in the aging brain, and the route of administration matters enormously for both efficacy and safety. Until we have rigorous phase III data, my role is to inform patients about what’s emerging without overselling what remains experimental.” Clinical Perspective While preclinical findings on CBD and CBG as potential neuroprotective agents against cognitive decline are encouraging, clinicians should recognize that in vitro and animal models often do not translate to human efficacy, and current evidence remains preliminary without published phase II or III trial data. The heterogeneity of cognitive decline etiologies (Alzheimer’s disease, vascular dementia, Lewy body disease, etc.) means that even if these cannabinoids prove beneficial, their effects may be disease-specific or population-dependent. Additionally, the regulatory status of cannabinoids remains uncertain in many jurisdictions, and standardization of dosing, purity, and formulation across products is inconsistent, complicating any recommendation for clinical use. Until robust human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) establish safety, efficacy, and optimal dosing in target populations, healthcare providers should counsel patients seeking [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for cognitive concerns that evidence-based interventions (cognitive stim 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Nasal%20Spray%20Shows%20Promise%20Against%20Cognitive%20Decline%20%7C%20Drug%20Discovery%20And%20Development%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56576)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56576)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Nasal%20Spray%20Shows%20Promise%20Against%20Cognitive%20Decline%20%7C%20Drug%20Discovery%20And%20Development%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56576)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.labroots.com/trending/drug-discovery-and-development/30593/nasal-spray-promise-cognitive-decline](https://www.labroots.com/trending/drug-discovery-and-development/30593/nasal-spray-promise-cognitive-decline) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).